Mml Investors Services, LLC Arcus Biosciences, Inc. Transaction History

Mml Investors Services, LLC

$27.4 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$23.23 - $30.07 $5,157 - $6,675	-222 Reduced 2.79%	7,741 $203,000
Q2 2022 Aug 12, 2022	BUY	$17.23 - $37.73 $3,618 - $7,923	210 Added 2.71%	7,963 $202,000
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $150,991 - $218,394	-5,221 Reduced 40.24%	7,753 $245,000
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $65,803 - $101,641	-2,097 Reduced 13.91%	12,974 $525,000
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $182,908 - $255,922	-6,792 Reduced 31.07%	15,071 $526,000
Q2 2021 Aug 13, 2021	SELL	$22.75 - $35.77 $27,937 - $43,925	-1,228 Reduced 5.32%	21,863 $600,000
Q1 2021 May 14, 2021	BUY	$26.16 - $41.39 $63,202 - $99,998	2,416 Added 11.69%	23,091 $648,000
Q4 2020 Feb 12, 2021	SELL	$17.0 - $32.36 $32,725 - $62,293	-1,925 Reduced 8.52%	20,675 $537,000
Q3 2020 Nov 13, 2020	BUY	$17.14 - $25.47 $110,501 - $164,205	6,447 Added 39.91%	22,600 $387,000
Q2 2020 Aug 14, 2020	SELL	$13.97 - $36.56 $277,472 - $726,154	-19,862 Reduced 55.15%	16,153 $399,000
Q1 2020 May 14, 2020	SELL	$8.78 - $19.28 $45,875 - $100,738	-5,225 Reduced 12.67%	36,015 $499,000
Q4 2019 Feb 11, 2020	BUY	$7.33 - $10.79 $35,865 - $52,795	4,893 Added 13.46%	41,240 $417,000
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $55,377 - $87,537	-8,599 Reduced 19.13%	36,347 $331,000
Q2 2019 Aug 13, 2019	SELL	$7.29 - $13.38 $47,122 - $86,488	-6,464 Reduced 12.57%	44,946 $357,000
Q1 2019 May 10, 2019	BUY	$8.95 - $12.49 $15,322 - $21,382	1,712 Added 3.44%	51,410 $642,000
Q4 2018 Feb 14, 2019	SELL	$9.74 - $14.5 $19,109 - $28,449	-1,962 Reduced 3.8%	49,698 $535,000
Q3 2018 Nov 07, 2018	BUY	$10.88 - $14.95 $379,929 - $522,054	34,920 Added 208.6%	51,660 $720,000
Q2 2018 Aug 13, 2018	BUY	$12.24 - $17.05 $204,897 - $285,417	16,740 New	16,740 $205,000

Others Institutions Holding RCUS

# of Institutions

200

Shares Held

51.5M

Call Options Held

236K

Put Options Held

141K

Black Rock Inc. New York, NY

9.76M
Shares

$139 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

5.47M
Shares

$77.7 Million
0.0% of portfolio
Woodline Partners LP San Francisco, CA

3.48M
Shares

$49.4 Million
0.48% of portfolio
State Street Corp Boston, MA

3.01M
Shares

$42.8 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

2.44M
Shares

$34.6 Million
0.1% of portfolio

View Full List

About Arcus Biosciences, Inc.

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

More about RCUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mml Investors Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mml Investors Services, LLC with notifications on news.

Account